OxTalks is Changing
Oxford Events, the new replacement for OxTalks, will launch on 16th March. From now until the launch of Oxford Events, new events cannot be published or edited on OxTalks while all existing records are migrated to the new platform. The existing OxTalks site will remain available to view during this period.
From 16th, Oxford Events will launch on a new website: events.ox.ac.uk, and event submissions will resume. You will need a Halo login to submit events. Full details are available on the Staff Gateway.
Immune determinants of checkpoint therapy efficacy and toxicity
In Person Only
The mechanisms underlying the efficacy and toxicity of anti-programmed cell death protein 1 (PD-1) and anti-cytotoxic T lymphocyte-associated protein 4 (CTLA-4) therapy are incompletely understood. First, by studying the programming of responding PD-1+CD8+ T (Tresp) cell populations from patients with advanced melanoma, we identified differential programming of Tresp cells in response to combination therapy, from an exhausted toward a more cytotoxic effector program. This effect does not occur with anti-PD-1 monotherapy. Single-cell transcriptome and T cell receptor repertoire analysis was used to identify altered effector programming of expanding PD-1+CD8+ T cell clones with distinct regulon usage, STAT1 and STAT3 utilization and antitumor specificity connected to interleukin (IL)-21 signaling in combination and anti-CTLA-4 monotherapy. Therapeutic efficacy of CTLA-4 blockade was lost in B16F10 melanoma models with either Il21r- deficiency or anti-IL-21 receptor blockade. Together, these results show how IL-21 signaling to TResp is critical for anti-CTLA-4-based checkpoint therapies and highlight major signaling differences to anti-PD-1 monotherapy. Nevertheless, checkpoint therapy induces significant and potential life-threatening immune-mediated side-effects, such as the liver. By spatial single-cell and transcriptomic analysis of the inflamed livers of checkpoint therapy induced-hepatitis (ICI-Hep) and spontaneous autoimmune hepatitis, we identify responding T cells as hallmarks of pathological liver inflammation and identify distinct interaction partners and therapeutically targetable signaling pathways. The presentation highlights differential pathways mediating the reprogramming of exhausted T cells downstream of checkpoint therapy.
Date:
21 January 2026, 12:30
Venue:
Kennedy Institute of Rheumatology, Headington OX3 7FY
Venue Details:
Kennedy Lecture Theatre
Speaker:
Prof. Dr. Dr. Bertram Bengsch (University of Freiburg)
Organising department:
Kennedy Institute of Rheumatology
Organiser:
Tess Lawless (Kennedy Institute of Rheumatology)
Hosts:
Carl Lee (Kennedy Institute of Rheumatology),
Prof Jagdeep Nanchahal (Professor of Hand,Plastic and Reconstructive surgery)
Part of:
Kennedy Institute Seminars
Booking required?:
Not required
Audience:
Members of the University only
Editor:
Theresa Lawless
